New Hypolipidemic Drugs

1978 ◽  
pp. 77-95 ◽  
Author(s):  
William L. Bencze
Keyword(s):  
Hypolipidemic Drugs

Berberine: A Promising Natural Isoquinoline Alkaloid for the Development of Hypolipidemic Drugs

2020 ◽  
Vol 20 (28) ◽  
pp. 2634-2647
Author(s):  
Dong-Dong Li ◽  
Pan Yu ◽  
Wei Xiao ◽  
Zhen-Zhong Wang ◽  
Lin-Guo Zhao
Keyword(s):  
Clinical Trials ◽  
Animal Models ◽  
Physicochemical Properties ◽  
Isoquinoline Alkaloid ◽  
Hypolipidemic Activity ◽  
Lipid Lowering ◽  
Lipid Lowering Drug ◽  
Lipid Lowering Agent ◽  
Lowering Drug ◽  
Hypolipidemic Drugs

: Berberine, as a representative isoquinoline alkaloid, exhibits significant hypolipidemic activity in both animal models and clinical trials. Recently, a large number of studies on the lipid-lowering mechanism of berberine and studies for improving its hypolipidemic activity have been reported, but for the most part, they have been either incomplete or not comprehensive. In addition, there have been a few specific reviews on the lipid-reducing effect of berberine. In this paper, the physicochemical properties, the lipid-lowering mechanism, and studies of the modification of berberine all are discussed to promote the development of berberine as a lipid-lowering agent. Subsequently, this paper provides some insights into the deficiencies of berberine in the study of lipid-lowering drug, and based on the situation, some proposals are put forward.

scholarly journals Differential Effect of Hypolipidemic Drugs on Lipoprotein-Associated Phospholipase A 2

2007 ◽  
Vol 27 (10) ◽  
pp. 2236-2243 ◽  
Author(s):  
Vasilios G. Saougos ◽  
Afroditi P. Tambaki ◽  
Mihalis Kalogirou ◽  
Michael Kostapanos ◽  
Irene F. Gazi ◽  
...  
Keyword(s):  
Differential Effect ◽  
Phospholipase A ◽  
Hypolipidemic Drugs ◽  
Phospholipase A 2

Hypolipidemic Drugs and Diabetes Mellitus—Mechanisms and Data From Genetic Trials

2018 ◽  
Vol 23 (3) ◽  
pp. 187-191 ◽  
Author(s):  
Theodosios D. Filippatos ◽  
Thalia Panagiotopoulou ◽  
Eleftheria Tzavella ◽  
Moses S. Elisaf
Keyword(s):  
Diabetes Mellitus ◽  
Hypolipidemic Drugs

scholarly journals Statin Induced Dysuria- A Case Report

2016 ◽  
Vol 01 (02) ◽  
pp. 028-030
Author(s):  
Radhika Soanker ◽  
Arun Jyothi ◽  
Sita ram
Keyword(s):  
Ldl Cholesterol ◽  
Lipid Lowering ◽  
Lipid Lowering Therapy ◽  
Primary Target ◽  
Short Term ◽  
Statin Group ◽  
Lowering Therapy ◽  
Hypolipidemic Drugs ◽  
Prevention Of Cardiovascular Disease

AbstractStatins are a class of hypolipidemic drugs, that are primarily used for the treatment of dyslipidemia and the prevention of cardiovascular disease. ATP III guidelines, 2002, recommends that LDL cholesterol be the primary target of therapy, and lipid lowering therapy may be initiated based on evaluation of short term and long term cardiovascular risk(1). We are report a case of dysuria follow statin group of drugs, which is not enlisted in the side effect of these drugs. In the present case after re-challenge with similar group of drug patient again developed the symptoms. Underlying hyperlipidemia was effectively controlled with Fenofibrates.

Sign in / Sign up

Export Citation Format

Share Document